US Stock MarketDetailed Quotes

SGMO Sangamo Therapeutics

Watchlist

0.574
-0.017-2.94%

Close Jun 7 16:00 ET

0.570
-0.004-0.75%

Post 19:09 ET

119.17MMarket Cap-307P/E (TTM)

Sangamo Therapeutics Stock Forum

Stock Region

May 10 18:56

Therapeutics Company Reveals Pre-clinical Data For Integrase Technology

The MINT platform, derived from Sangamo's extensive experience in protein-DNA interactions through its zinc finger technology.
Sangamo Therapeutics recently presented critical pre-clinical data on its innovative next-generation integrase technology, the Modular Integrase (MINT) platform, highlighting a significant advancement in the field of genome editing. The announcement came as part of their participation at the 27th Amer...

Trytosaveabit

Apr 23 04:37

Anxious to see data!

$Sangamo Therapeutics(SGMO.US)$ Sangamo Therapeutics To Present Neurology-Focused Pre-Clinical Data From Epigenetic Regulation, Capsid Delivery And Genome Engineering Platforms At 27th ASGCT Annual Meeting

Trytosaveabit

Apr 2 23:42

One of these days soon you will get the attention you so much deserve!

$Sangamo Therapeutics(SGMO.US)$ Hehehe! just thinking outloud

Moomoo AI

Mar 14 03:30

The market anticipates continued poor revenue growth, potentially suppressing the P/S ratio. The company's forecast of declining revenue contributes to its low P/S. Without major changes, a drastic stock price increase seems unlikely.

There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 50% Share Price Rise

Trytosaveabit

Mar 13 20:09

$Sangamo Therapeutics(SGMO.US)$ Sangamo Therapeutics Announces Data From STAC-BBB Demonstrating 'Robust Penetration of the Blood-brain Barrier (BBB) and Strong Transgene Expression Throughout the Central Nervous System (CNS) of NHPs'